Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.57 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923981 | 0.88 | HTR1A (0.48) | HTR1ASLC6A2SLC6A3SLC6A4GBA1 | |
| SCHEMBL6929054 | 0.87 | HTR1A (0.58) | HTR1ASLC6A2SLC6A3SLC6A4GBA1 | |
| SCHEMBL6929805 | 0.86 | HTR1A (0.44) | HTR1ASLC6A2SLC6A3SLC6A4GBA1 | |
| SCHEMBL6922676 | 0.84 | SLC6A4 (0.59) | HTR1ASLC6A2SLC6A3SLC6A4GBA1 | |
| SCHEMBL3965587 | 0.82 | GBA1 (0.56) | HTR1ASLC6A2SLC6A3SLC6A4GBA1 | |
| SCHEMBL7526768 | 0.82 | SLC6A4 (0.56) | HTR1ASLC6A2SLC6A3SLC6A4GBA1 | |
| SCHEMBL6928732 | 0.82 | SLC6A4 (0.49) | HTR1ASLC6A2SLC6A3SLC6A4GBA1 | |
| SCHEMBL6929055 | 0.82 | HTR1A (0.55) | HTR1ASLC6A2SLC6A3SLC6A4GBA1 | |
| SCHEMBL6922636 | 0.82 | SLC6A4 (0.50) | HTR1ASLC6A2SLC6A3SLC6A4GBA1 | |
| SCHEMBL1155850 | 0.81 | SLC6A2 (0.49) | HTR1ASLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518284-B2 | For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary | FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) | 2003-02-11 | — | — | US | claimed |
| US-20020038031-A1 | New 4 - substituted piperidines | ORJALES VENERO AURELIO (ES) | 2002-03-28 | — | — | US | claimed |
| EP-1002794-A1 | 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors | FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) | 2000-05-24 | — | — | EP | claimed |
| US-6518284-B2 | For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary | FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) | 2003-02-11 | — | — | US | disclosed |
| US-20020038031-A1 | New 4 - substituted piperidines | ORJALES VENERO AURELIO (ES) | 2002-03-28 | — | — | US | disclosed |
| EP-1002794-A1 | 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors | FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) | 2000-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038031-A1 | New 4 - substituted piperidines | ADRA2C, ADRB2, ADRB1 | HTR1A 16/4885SLC6A2 12/4885SLC6A3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.